Related Experiment Videos
Update on hepatocellular carcinoma: Pathologists' review.
Tony El Jabbour1, Stephen M Lagana2, Hwajeong Lee3
1Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, United States.
World Journal of Gastroenterology
|April 24, 2019
Summary
This review updates hepatocellular carcinoma (HCC) classification using molecular pathology and immunohistochemistry. Updated sub-classification improves diagnosis, prognosis prediction, and targeted therapy selection for HCC patients.
Area of Science:
- Pathology
- Oncology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) exhibits significant histopathologic diversity with recognized subtypes.
- Advances in molecular pathology and understanding of biologic features are driving updated HCC classifications.
Purpose of the Study:
- To review and update the pathologic sub-classification of hepatocellular carcinoma (HCC).
- To highlight the role of biomarkers in diagnosis, prognosis, and theranostics for HCC.
- To summarize specific HCC subtypes and the consensus on combined HCC-cholangiocarcinoma.
Main Methods:
- Review of current literature on HCC histopathology and molecular pathology.
- Analysis of diagnostic approaches and prognostic biomarkers in HCC.
- Summary of histopathology for specific HCC subtypes and combined HCC-cholangiocarcinoma.
Main Results:
- Updated classifications enhance diagnostic accuracy and enable stratification into biologically meaningful HCC subgroups.
- Immunohistochemical and molecular testing are crucial for predicting HCC patient prognosis.
- Theranostic data from pathologists is increasingly important for targeted therapy in HCC.
Conclusions:
- Pathologic sub-classification of HCC is evolving with molecular and immunologic insights.
- Biomarkers play a critical role in HCC diagnosis, prognosis, and guiding targeted therapies.
- Further research into novel biomarkers and stratification approaches will refine HCC management.